Found: 5
Select item for more details and to access through your institution.
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
- Published in:
- Cancer Management & Research, 2018, v. 10, p. 1015, doi. 10.2147/CMAR.S162714
- By:
- Publication type:
- Article
A phase 1 study of lucatumumab, a fully human anti- CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 159, n. 1, p. 58, doi. 10.1111/j.1365-2141.2012.09251.x
- By:
- Publication type:
- Article
Phase IA/ II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non- Hodgkin or Hodgkin lymphoma.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 2, p. 258, doi. 10.1111/bjh.12630
- By:
- Publication type:
- Article
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer.
- Published in:
- Breast Cancer: Targets & Therapy, 2018, v. 11, p. 69, doi. 10.2147/BCTT.S162841
- By:
- Publication type:
- Article
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 3, p. 763, doi. 10.1007/s00262-020-02730-5
- By:
- Publication type:
- Article